Market Overview:

The global neurostimulation devices market reached a value of US$ 7.0 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 13.4 Billion by 2027, exhibiting a CAGR of 12.3% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor. 

A neurostimulation device is a programmable medical transmitter that can deliver electrical signals to the specific parts of the human brain. It is also used to stimulate, inhibit, modify, regulate and alter the activity of the autonomous, central and peripheral nervous systems in the patient’s body. This primarily aids in the treatment of various medical ailments, such as movement disorders, chronic pain and epilepsy. It is also utilized in the operation of neural prosthetics, hearing aids, artificial vision, artificial limbs and brain-machine interfaces. Neurostimulation devices can be both implantable or externally placed.

The rising instances of neurological and lifestyle-related disorders, along with the rapidly growing geriatric population across the globe, are among the key factors driving the growth of the market. Furthermore, the increasing preference for minimally invasive (MI) procedures among patients is also providing a boost to the market growth. For instance, deep brain stimulation (DBS) is an MI procedure that uses neurostimulation devices to deliver electrical signals to a specific spot in the brain circuits. This aids in treating various degenerative disorders, such as Parkinson’s and Alzheimer’s disease. Additionally, technological advancements, including the development of devices that can electronically stimulate the nervous system to restore vision and regain post-paralysis motor movements, are creating a positive outlook for the market. Other factors, including significant growth in the medical industry, increasing healthcare expenditure and extensive research and development (R&D) activities, are projected to drive the market in the upcoming years.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global neurostimulation devices market, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on stimulation type, device type, application and end-user.

Breakup by Stimulation Type:

• Internal Stimulation
• External Stimulation

Breakup by Device Type:

• SCS (Spinal Cord Stimulation) Devices
• DBS (Deep Brain Stimulation) Devices
• SNS (Sacral Nerve Stimulation) Devices
• VNS (Vagus Nerve Stimulation) Devices
• GES (Gastric Electrical Stimulation) Devices
• Transcutaneous Electrical Nerve Stimulation Devices
• Transcranial Magnetic Stimulation Devices
• Others
   

Breakup by Application:

• Pain Management
• Epilepsy
• Essential Tremors
• Urinary and Fecal Incontinence
• Depression
• Dystonia
• Parkinson’s Disease
• Others
   

Breakup by End-User:

• Rehabilitation Centers
• Hospitals
• Medical Clinics
• Others
   

Breakup by Region:

• North America
  • United States
  • Canada
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa
   

Competitive Landscape:

The competitive landscape of the industry has also been examined with some of the key players being Biocontrol Medical, Boston Scientific Corporation, Cyberonics Inc., Medtronic Inc., Neuronetics Inc., Neuropace Inc., Neurosigma Inc., Nevro Corporation, ST. Jude Medical Inc., Synapse Biomedical Inc., etc.

Report Coverage: